Study flow chart. by Karl Ingard (22582091)

Subjects:

Kaplan-Meier curve of the primary outcome. by Karl Ingard (22582091)

Subjects:

Number of Patients Who Reached the Primary and Secondary Endpoints During Follow-up. by Karl Ingard (22582091)

Subjects:

Subgroup Analysis of the Occurrence of the Primary Endpoint and Its Components. by Karl Ingard (22582091)

Subjects:

Line graph illustrating mean random blood glucose (mmol/L) at weekly intervals during the induction phase. by Elsie D. Oduor (22521785)

Subjects:

Line graph illustrating mean random blood glucose (mmol/L) at weekly intervals during the treatment phase. by Elsie D. Oduor (22521785)

Subjects:

Significant repeated measurements sEMG outcomes. by María Benito-de-Pedro (22057468)

Subjects:

Significant single measurement sEMG outcomes. by María Benito-de-Pedro (22057468)

Subjects:

Differences in total Tau and p-Tau Thr231 following maternal Pg-OMV exposure. by Adrienne J. Bradley (20861948)

Subjects:

The presence of the gRNA targeting <i>OPG147</i> has no effect on transcription of viral entry and early genes. by Xue-Mei Yi (18851202)

Mutation of vOPG147 F55, T116 and T117 does not affect replication and production of VACV. by Xue-Mei Yi (18851202)

vOPG147-deficiency promotes innate immune response to VACV. by Xue-Mei Yi (18851202)

OPG147 is associated with MITA. by Xue-Mei Yi (18851202)

OPG147-deficiency promotes innate immune response to MPXV. by Xue-Mei Yi (18851202)

OPG147 contributes to VACV evasion of host defense and is a virulence factor <i>in vivo.</i> by Xue-Mei Yi (18851202)

RT-qPCR evaluation of MYD88, NLRP3, and NFκβ in GA 18.5 pup brains. by Adrienne J. Bradley (20861948)

Subjects:

Decadal mean regional hydrology. by Nic Gedney (19762301)

Patient demographics. by Yongwoo Lee (2265172)

Subjects:

Flowchart of overall study protocol. by Yongwoo Lee (2265172)

Subjects:

Table 6 - Gain and loss: Human and environmental wellbeing – drivers of Kilimanjaro’s decreasing biodiversity by Andreas Hemp (730415)